Publications
Recent articles from PubMed
315. Circulating cancer giant cells with unique characteristics frequently found in patients with myelodysplastic syndromes (MDS). Ali AM, BenMohamed F, Decina A, Mukherjee S, Levi S, Garrido Castillo LN, Bréchot D, Jurcic J, Raza A, Paterlini Bréchot P. Med Oncol. 2023 Jun 14;40(7):204. doi: 10.1007/s12032-023-02064-z.
314. Mutation in SF3B1 gene promotes formation of polyploid giant cells in Leukemia cells. Mukherjee S, Ali AM, Murty VV, Raza A. Med Oncol. 2022 Apr 28;39(5):65. doi: 10.1007/s12032-022-01652-9.
313. Subversion of Serotonin Receptor Signaling in Osteoblasts by Kynurenine Drives Acute Myeloid Leukemia. Galán-Díez M, Borot F, Ali AM, Zhao J, Gil-Iturbe E, Shan X, Luo N, Liu Y, Huang XP, Bisikirska B, Labella R, Kurland I, Roth BL, Quick M, Mukherjee S, Rabadán R, Carroll M, Raza A, Kousteni S. Cancer Discov. 2022 Apr 1;12(4):1106-1127. doi: 10.1158/2159-8290.CD-21-0692.
312. SF3B1 mutant-induced missplicing of MAP3K7 causes anemia in myelodysplastic syndromes. Lieu YK, Liu Z, Ali AM, Wei X, Penson A, Zhang J, An X, Rabadan R, Raza A, Manley JL, Mukherjee S. Proc Natl Acad Sci U S A. 2022 Jan 4;119(1):e2111703119. doi: 10.1073/pnas.2111703119.
311. Comprehensive phenotyping of erythropoiesis in human bone marrow: Evaluation of normal and ineffective erythropoiesis. Yan H, Ali A, Blanc L, Narla A, Lane JM, Gao E, Papoin J, Hale J, Hillyer CD, Taylor N, Gallagher PG, Raza A, Kinet S, Mohandas N. Am J Hematol. 2021 Sep 1;96(9):1064-1076. doi: 10.1002/ajh.26247. Epub 2021 Jun 3.
310. Novel multicancer early detection technology-potential value to employers and the workforce. Ofman JJ, Fendrick AM, Raza A. Am J Manag Care. 2020 Dec;26(10 Spec No.):SP363. doi: 10.37765/ajmc.2020.88567.
309. Imetelstat Achieves Meaningful and Durable Transfusion Independence in High Transfusion-Burden Patients With Lower-Risk Myelodysplastic Syndromes in a Phase II Study. Steensma DP, Fenaux P, Van Eygen K, Raza A, Santini V, Germing U, Font P, Diez-Campelo M, Thepot S, Vellenga E, Patnaik MM, Jang JH, Varsos H, Bussolari J, Rose E, Sherman L, Sun L, Wan Y, Dougherty S, Huang F, Feller F, Rizo A, Platzbecker U. J Clin Oncol. 2021 Jan 1;39(1):48-56. doi: 10.1200/JCO.20.01895. Epub 2020 Oct 27.
308. Rewriting the rules for care of MDS and AML patients in the time of COVID-19. Raza A, Assal A, Ali AM, Jurcic JG. Leuk Res Rep. 2020 Apr 20:100201.
307. Disease-Causing Mutations in SF3B1 Alter Splicing by Disrupting Interaction with SUGP1. Zhang J, Ali AM, Lieu YK, Liu Z, Gao J, Rabadan R, Raza A, Mukherjee S, Manley JL. Mol Cell. 2019 Oct 3;76(1):82-95.e7.
306. Borot F, Wang H, Ma Y, Jafarov T, Raza A, Ali, AM, Mukherjee, S. Gene-edited stem cells enable CD33-directed Immune therapy for myeloid malignancies. Proceedings of the National Academy of Sciences (2019) 116(24: 11978-11987.
305. Improving Treatment for Myelodysplastic Syndromes Patients. Montoro J, Yerlikaya A, Ali A, Raza A. Curr Treat Options Oncol. 2018 Oct 25;19(12):66.
304. Gnanapragasam MN, Crispino JD, Ali AM, Weinberg R, Hoffman R, Raza A & Bieker JJ. Survey and evaluation of mutations in the human KLF1 transcription unit. Scientific Reports (2018) 8:6587.
303. Ali AM, Huang Y, Pinheiro RF, Xue F, Hu J, Iverson N, Hoehn D, Coutinho DF, Kayani J, Chernak B, Lane J, Hillyer CD, Galili N, Jurcic J, Mohandas N, An X, Raza. Severely impaired terminal erythroid differentiation as an independent prognostic marker in myelodysplastic syndromes. Blood Advances (2018) 2:1393-1402.
302. Abel GA, Efficace F, Buckstein RJ, Tinsley S, Jurcic JG, Martins Y, Steensma DP, Watts CD, Raza A, Lee SJ, List AF, Klaassen RJ. Prospective international validation of the Quality of Life in Myelodysplasia Scale (QUALMS). Haematologica. 2016 Jun;101(6):781-8. doi: 10.3324/haematol.2015.140335.
301. Borthakur G, Popplewell L, Boyiadzis M, Foran J, Platzbecker U, Vey N, Walter RB, Olin R, Raza A, Giagounidis A, Al-Kali A, Jabbour E, Kadia T, Garcia-Manero G, Bauman JW, Wu Y, Liu Y, Schramek D, Cox DS, Wissel P, Kantarjian H. Activity of the oral mitogen-activated protein kinase kinase inhibitor trametinib in RAS-mutant relapsed or refractory myeloid malignancies. Cancer. 2016 Jun 15;122(12):1871-9. doi: 10.1002/cncr.29986. Erratum in: Cancer. 2016 Oct 15;122(20):3246.
300. Obeng EA, Chappell RJ, Seiler M, Chen MC, Campagna DR, Schmidt PJ, Schneider RK, Lord AM, Wang L, Gambe RG, McConkey ME, Ali AM, Raza A, Yu L, Buonamici S, Smith PG, Mullally A, Wu CJ, Fleming MD, Ebert BL. Physiologic Expression of Sf3b1(K700E) Causes Impaired Erythropoiesis, Aberrant Splicing, and Sensitivity to Therapeutic Spliceosome Modulation. Cancer Cell. 2016 Sep 12;30(3):404-17. doi: 10.1016/j.ccell.2016.08.006.
299. Suzukida J, Kaley K, Raza A, Saif MW. Therapy-Associated Myeloid Dysplasia in a Long-Surviving Patient with Pancreatic Cancer. Cureus. 2016 Jul 13;8(7):e687. doi: 10.7759/cureus.687.
298. Abdullah Ali and Azra Raza: Two different “tales” of ATG7: clinical relevance to Myelodysplastic syndromes. Mol Cellular Oncol, Volume 3, Issue 5, 2016.
297. Sung Mi Park, Jianhong Ou,2 Lynn Chamberlain, Tessa M. Simone, Huan Yang,Ching-Man Virbasius, Abdullah M. Ali, Lihua J. Zhu, Siddhartha Mukherjee, Azra Raza, Michael R. Green. U2AF35(S34F) Promotes Transformation by Directing Aberrant ATG7 Pre-mRNA 3’ End Formation. Mol Cell 2016; 62:479-90
296. Abel GA, Efficace F, Buckstein RJ, Tinsley S, Jurcic JG, Martins Y, Steensma DP, Watts CD, Raza A, Lee SJ, List AF, Klaassen RJ. Prospective international validation of the Quality of Life in Myelodysplasia Scale (QUALMS). Haematologica. 2016 Mar 4. pii: haematol.2015.140335. [Epub ahead of print]
295. Zhang J, Lieu YK, Ali AM, Penson A, Reggio KS, Rabadan R, Raza A, Mukherjee S, Manley JL. Disease-associated mutation in SRSF2 misregulates splicing by altering RNA-binding affinities. Proc Natl Acad Sci U S A. 2015 Aug 10. pii: 201514105.
294. Silverman LR, Greenberg P, Raza A, Olnes MJ, Holland JF, Reddy P, Maniar M, Wilhelm F. Clinical activity and safety of the dual pathway inhibitor rigosertib for higher risk myelodysplastic syndromes following DNA methyltransferase inhibitor therapy. Hematol Oncol. 2015 Jun;33(2):57-66
293. Verstovsek S, Mesa RA, Gotlib J, Levy RS, Gupta V, DiPersio JF, Catalano JV, Deininger MW, Miller CB, Silver RT, Talpaz M, Winton EF, Harvey JH Jr, Arcasoy MO, Hexner EO, Lyons RM, Raza A, Vaddi K, Sun W, Peng W, Sandor V, Kantarjian H; COMFORT-I investigators. Efficacy, safety, and survival with ruxolitinib in patients with myelofibrosis: results of a median 3-year follow-up of COMFORT-I. Haematologica. 2015 Apr;100(4):479-88.
292. Raza, Azra, Nicholas Iverson, and Abdullah M. Ali. “Developments in the treatment of transfusion-dependent anemia in patients with myelodysplastic syndromes: epidemiology, etiology, genetics, and targeted therapies.” Advances in Genomics & Genetics 4 (2014).
291. Mohammed Salhab, Ali Zaidi, Iffat Adeel, Sana Saeed, Azra Raza et al. Three Cases of Refractory Anemia with Ringed Sideroblasts Who Responded to Chloroquine. J Blood Lymph 4:125, 2014.
290. Silverman LR, Greenberg P, Raza A, Olnes MJ, Holland JF, Reddy P, Maniar M, Wilhelm F. Clinical activity and safety of the dual pathway inhibitor rigosertib for higher risk myelodysplastic syndromes following DNA methyltransferase inhibitor therapy. Hematol Oncol. 2014 Apr 29. doi: 10.1002/hon.2137.
289. Arellano ML, Borthakur G, Berger M, Luer J, Raza A. A Phase II, Multicenter, Open-Label Study of Obatoclax Mesylate in Patients With Previously Untreated Myelodysplastic Syndromes With Anemia or Thrombocytopenia. Clin Lymphoma Myeloma Leuk. 2014 Dec;14(6):534-9.
288. Krevvata M, Silva BC, Manavalan JS, Galan-Diez M, Kode A, Matthews BG, Park D, Zhang CA, Galili N, Nickolas TL, Dempster DW, Dougall W, Teruya-Feldstein J, Economides AN, Kalajzic I, Raza A, Berman E, Mukherjee S, Bhagat G, Kousteni S. Inhibition of leukemia cell engraftment and disease progression in mice by osteoblasts. Blood. 2014 Oct 30;124(18):2834-46.
287. Schimmer AD, Raza A, Carter TH, Claxton D, Erba H, DeAngelo DJ, Tallman MS, Goard C, Borthakur G. A multicenter phase I/II study of obatoclax mesylate administered as a 3- or 24-hour infusion in older patients with previously untreated acute myeloid leukemia. PLoS One. 2014 Oct 6;9(10):e108694. doi: 10.1371/journal.pone.0108694. eCollection 2014.
286. Raza A, Ravandi F, Rastogi A, Bubis J, Lim SH, Weitz I, Castro-Malaspina H, Galili N, Jawde RA, Illingworth A. A prospective multicenter study of paroxysmal nocturnal hemoglobinuria cells in patients with bone marrow failure. Cytometry B Clin Cytom. 2014 May;86(3):175-82. doi: 10.1002/cyto.b.21139. Epub 2013 Nov 12.
285. Mesa RA, Kiladjian JJ, Verstovsek S, Al-Ali HK, Gotlib JR, Gisslinger H, Levy RS, Siulnik A, Gupta V, Khan M, Dipersio JF, McQuitty M, Catalano JV, Hunter DS, Knoops L, Deininger M, Cervantes F, Miller C, Vannucchi AM, Silver RT, Barbui T, Talpaz M, Barosi G, Winton EF, Mendeson E, Harvey JH, Arcasoy MO, Hexner E, Lyons RM, Paquette R, Raza A, Sun W, Sandor V, Kantarjian HM, Harrison C. Efficacy, safety and survival with ruxolitinib in patients with myelofibrosis: results of a median 2-year follow-up of COMFORT-I. Haematologica. 2013 Dec;98(12):1865-71. doi: 10.3324/haematol.2013.092155. Epub 2013 Sep 13
284. Verstovsek S, Mesa RA, Gotlib J, Levy RS, Gupta V, DiPersio JF, Catalano JV, Deininger MW, Miller CB, Silver RT, Talpaz M, Winton EF, Harvey JH Jr, Arcasoy MO, Hexner EO, Lyons RM, Paquette R, Raza A, Vaddi K, Erickson-Viitanen S, Sun W, Sandor V, Kantarjian HM. Efficacy, safety and survival with ruxolitinib in patients with myelofibrosis: results of a median 2-year follow-up of COMFORT-I. Haematologica. 2013 Dec;98(12):1865-71. doi: 10.3324/haematol.2013.092155. Epub 2013 Sep 13.
283. Raza A, Ravandi F, Rastogi A, Bubis J, Lim SH, Weitz I, Castro-Malaspina H, Galili N, Jawde RA, Illingworth A. A prospective multicenter study of paroxysmal nocturnal hemoglobinuria cells in patients with bone marrow failure. Cytometry B Clin Cytom. 2013 Nov 12. doi: 10.1002/cyto.b.21139. [Epub ahead of print]
282. Kode A, Manavalan JS, Mosialou I, Bhagat G, Rathinam CV, Luo N, Khiabanian H, Lee A, Murty VV, Friedman R, Brum A, Park D, Galili N, Mukherjee S, Teruya-Feldstein J, Raza A, Rabadan R, Berman E, Kousteni S. Leukaemogenesis induced by an activating β-catenin mutation in osteoblasts. Nature. 506:240-244, 2014
281. Hu J, Liu J, Xue F, Halverson G, Reid M, Guo A, Chen L, Raza A, Galili N, Jaffray J, Lane J, Chasis JA, Taylor N, Mohandas N, An X. Isolation and functional characterization of human erythroblasts at distinct stages: implications for understanding of normal and disordered erythropoiesis in vivo. Blood. 2013 Apr 18;121(16):3246-53. doi: 10.1182/blood-2013-01-476390. Epub 2013 Feb 19. 2013
280. Zhan H, Cardozo C, Raza A. MicroRNAs in myeloproliferative neoplasms. Br J Haematol. 2013 May;161(4):471-83. doi: 10.1111/bjh.12276. Epub 2013 Feb 25. Review. 2013
279. Verstovsek S, Mesa RA, Gotlib J, Levy RS, Gupta V, DiPersio JF, Catalano JV, Deininger M, Miller C, Silver RT, Talpaz M, Winton EF, Harvey JH Jr, Arcasoy MO, Hexner E, Lyons RM, Paquette R, Raza A, Vaddi K, Erickson-Viitanen S, Sun W, Sandor V, Kantarjian HM. The clinical benefit of ruxolitinib across patient subgroups: analysis of a placebo-controlled, Phase III study in patients with myelofibrosis. Br J Haematol. 2013 May;161(4):508-16. doi: 10.1111/bjh.12274. Epub 2013 Mar 11. 2013
278. Komrokji RS, Raza A, Lancet JE, Ren C, Taft D, Maniar M, Wilhelm F, List AF. Phase I clinical trial of oral rigosertib in patients with myelodysplastic syndromes. Br J Haematol. 2013 Aug;162(4):517-24. doi: 10.1111/bjh.12436. Epub 2013 Jun 21. 2013
277. Mesa RA, Kiladjian JJ, Verstovsek S, Al-Ali HK, Gotlib JR, Gisslinger H, Levy RS, Siulnik A, Gupta V, Khan M, Dipersio JF, McQuitty M, Catalano JV, Hunter DS, Knoops L, Deininger M, Cervantes F, Miller C, Vannucchi AM, Silver RT, Barbui T, Talpaz M, Barosi G, Winton EF, Mendeson E, Harvey JH, Arcasoy MO, Hexner E, Lyons RM, Paquette R, Raza A, Sun W, Sandor V, Kantarjian HM, Harrison C. Comparison of placebo and best available therapy for the treatment of myelofibrosis in the phase 3 COMFORT studies. Haematologica. 2013 Aug 2. [Epub ahead of print] 2013
276. Verstovsek S, Mesa RA, Gotlib J, Levy RS, Gupta V, Dipersio JF, Catalano JV, Deininger MW, Miller CB, Silver RT, Talpaz M, Winton EF, Harvey JH, Arcasoy MO, Hexner EO, Lyons RM, Paquette R, Raza A, Vaddi K, Erickson-Viitanen S, Sun W, Sandor V, Kantarjian HM. Efficacy, safety and survival with ruxolitinib treatment in patients with myelofibrosis: results of a median 2-year follow-up of COMFORT-I. Haematologica. 2013 Sep 13. [Epub ahead of print] 2013
275. Raza A, Galili N. The biology and treatment of myelodysplastic syndromes. Rinsho Ketsueki. Oct;54(10):1730-6, 2013
274. Raza A, Galili N. Myelodysplastic Syndromes. Nature Cancer Reviews, (12):850-859, 2012.
273. List, M.R. Baer, D. Steensma, A. Raza, J. Esposito, N. Martinez-Lopez, C. Paley, J. Feigert, E. Besa Deferasirox Reduces Serum Ferritin and Labile Plasma Iron in Iron-Overloaded Patients with Myelodysplastic Syndromes. J Clin Oncol. 2012 Jun 10;30(17):2134-9. Epub 2012 Apr 30.
272. Raza A, Galili N, Mulford D, Smith SE, Brown G, Steensma DP, Lyons RM, Boccia R, Sekeres MA, Guillermo GM, Mesa RA. Phase 1 dose-ranging study of ezatiostat hydrochloride in combination with lenalidomide in patients with non-deletion (5q) low to intermediate-1 risk myelodysplastic syndrome (MDS). J Hematol Oncol. 2012 Apr 30;5(1):18. [Epub ahead of print]
271. Naomi Galili, Pablo Tamayo, Olga B Botvinnik, Jill P Mesirov, Margarita Roserika Brooks, Gail Brown and Azra Raza. Prediction of response to therapy with TLK199 in lower risk myelodysplastic syndromes. Journal of Hematology & Oncology, 5:20-28, 2012.
270. Jennifer Zikria, MD; Naomi Galili, PhD; Wei Yann Tsai, PhD; Huichun Zhan, MD; Xiaomei Ma, PhD; Azra Raza, MD. Thrombocytosis in Myelodysplastic Syndromes: Not an Innocent Bystander. J. Blood Disord Transfus. S3:002 (2012).
269. Naomi Galili1, Vladimir Trifonov2, Mark Ewalt3, Gerald Gehr4, Muhammad Mumtaz1, Siddhartha Mukherjee1, Raul Rabadan2, Azra Raza1† Identification of Dido1 mutation associated with familial myelodysplastic syndromes. Submitted to Blood, 2012.
268. Xiaomae Ma, Jennifer Zikria, Naomi Galili, Azra Raza. Impact of Hypomethylating Agents on the Cost of Care and Survival of Myelodysplastic Syndromes in the United States. December 2011.
267. Rafael Bejar, M.D., Ph.D., Kristen Stevenson, M.S., Bennett Caughey, Omar Abdel-Wahab, M.D., Ph.D., Naomi Galili, Ph.D., Azra Raza, M.D. , Hagop Kantarjian, M.D., Ross L. Levine, M.D., Donna Neuberg, Sc.D, Guillermo Garcia-Manero, M.D., Benjamin L. Ebert M.D., Ph.D. Validation of a Prognostic Model and the Impact of SF3B1, DNMT3A, and Other Mutations in 288 Genetically Characterized Lower Risk MDS Patient Samples. J Clin Oncol. 30, 3376–3382 (2012).
266. Srdan Verstovsek, M.D., Ph.D., Ruben A. Mesa, M.D., Jason R. Gotlib, M.D., Richard S. Levy, M.D., Vikas Gupta, M.D., M.R.C.P., John F. DiPersio, M.D., Ph.D., John V. Catalano, M.D., Michael Deininger, M.D., Ph.D., Carole Miller, M.D., Richard T. Silver, M.D., Moshe Talpaz, M.D., Elliott F. Winton, M.D., Jimmie H. Harvey, Jr., M.D., Murat O. Arcasoy, M.D, Elizabeth Hexner, M.D., Roger M. Lyons, M.D., Ronald Paquette, M.D., Azra Raza, M.D., Kris Vaddi, Ph.D., Susan Erickson-Viitanen, William Sun, Victor Sandor, M.D., Hagop M. Kantarjian, M.D. Ruxolitinib for the Treatment of Myelofibrosis: Results of a Double-Blind Placebo-Controlled Trial. New Engl J Med 1;366(9):799-807, March 2012.
265. Schecter J, Galili N and Raza A. MDS: Refining existing therapy through improved biologic insights. In Press, Blood Reviews. July 2011.
264. Bejanyan N, Tiu RV, Raza A, Jankowska A, Kalaycio M, Advani A, Chan J, Saunthararajah Y, Mooney L, Maciejewski JP, Sekeres MA. A phase 2 trial of combination therapy with thalidomide, arsenic trioxide, dexamethasone, and ascorbic acid (TADA) in patients with overlap myelodysplastic/myeloproliferative neoplasms (MDS/MPN) or primary myelofibrosis (PMF).Cancer. 2011 Dec 16. doi: 10.1002/cncr.26741. [Epub ahead of print]
263. Raza A, Galili N, Smith SE, Godwin J, Boccia RV, Myint H, Mahadevan D, Mulford D, Rarick M, Brown GL, Schaar D, Faderl S, Komrokji RS, List AF, Sekeres M. A phase 2 randomized multicenter study of 2 extended dosing schedules of oral ezatiostat in low to intermediate-1 risk myelodysplastic syndrome. Cancer. 2012 Apr 15;118(8):2138-47
262. Raza A, Oberstein P and Galili N. Synthetic Lethality: A proposal to overcome the regrowth resistance of Flt-3 ligand addicted cells. Blood, 2011 117:6987-6990; published ahead of print May 17, 2011, doi:10.1182/blood-2011-03-340273
261. Rafael Bejar, M.D., Ph.D., Kristen Stevenson, M.S., Omar Abdel-Wahab, M.D., Naomi Galili, Ph.D., Björn Nilsson, M.D., Ph.D., Guillermo Garcia-Manero, M.D., Hagop Kantarjian, M.D., Azra Raza, M.D., Ross L. Levine, M.D., Donna Neuberg, Sc.D., and Benjamin L. Ebert, M.D., Ph.D. Clinical Effect of Point Mutations in Myelodysplastic Syndromes. N Engl J Med 2011; 364:2496-2506, June 2011.
260. Kumar MS, Narla A, Nonami A, Mullally A, Dimitrova N, Ball B, McAuley JR, Poveromo L, Kutok JL, Galili N, Raza A, Attar E, Gilliland DG, Jacks T, Ebert BL. Coordinate loss of microRNA and protein-coding gene cooperate in the pathogenesis of 5q- syndrome. Blood: 27;118(17):4666-73, 2011.
259. Mark Ewalt, MD, Naomi Galili PhD, Muhammad Mumtaz, Michael Churchill, Sharon Rivera, Florence Borot, Azra Raza MD, Siddhartha Mukherjee MD PhD. DNMT3a mutations in high risk myelodysplastic syndrome parallel those found in acute myeloid leukemia. Blood Cancer. 2011; 1: e9.
258. Xiaomae Ma, Rong Wang; Naomi Galili; Susan Taylor Mayne; Sa A Wang; Azra Raza. Cigarette Smoking Shortens the Survival of Patients with Low-Risk Myelodysplastic Syndromes. Cancer Causes Control. 2011 Apr;22(4):623-9.
257. Wang R, Gross CP, Maggiore RJ, Halene S, Soulos PR, Raza A, Galili N, Ma X. Pattern of hypomethylating agents use among elderly patients with myelodysplastic syndromes. Leuk Res. 2011 Jul;35(7):904-8. Epub 2010 Nov 9.
256. Raza, A and Galili, N. Myelodysplastic Syndromes: Unexpected insights stimulate the biologic landscape. European Haematology, 2010;4:30–33
255. Wang SA, Abruzzo LV, Hasserjian RP, Zhang L, Hu Y, Zhang Y, Zhao M, Galili N, Raza A, Medeiros LJ, Garcia-Manero G, Miranda RN. Myelodysplastic syndromes with deletions of chromosome 11q lack cryptic MLL rearrangement and exhibit characteristic clinicopathologic features. Leuk Res. 2010 Aug 4. [Epub ahead of print]
254. Galili N, Raza A. Pharmacotherapy of myelodysplastic syndromes.Expert Opin Pharmacother. 2010 Aug;11(11):1889-99.
253. Raza A, Cruz R, Latif T, Mukhurjee S, Galili N. The Biology of Myelodysplastic Syndromes: Unity despite Heterogeneity. Hematology Reviews, Vol 2, No 1 (2010)
252. Fahd Quddus, Jessica Clima, Helen Seedham, Ghulam Sajjad, Naomi Galili and Azra Raza. Oral Ezatiostat HCl (TLK199) and Myelodysplastic syndrome: A case report of sustained hematologic response following an abbreviated exposure. Journal of Hematology & Oncology 2010, 3:16 doi:10.1186/1756-8722-3-16
251. Zaidi SK, Dowdy CR, van Wijnen AJ, Lian JB, Raza A, Stein JL, Croce CM, Stein GS. Altered Runx1 subnuclear targeting enhances myeloid cell proliferation and blocks differentiation by activating a miR-24/MKP-7/MAPK network. Cancer Res. 2009 Nov 1;69(21):8249-55. Epub 2009 Oct 13
250. Galili N, Qasim SA and Raza A. Defective ribosome biogenesis in Myelodysplastic Syndromes. 2009 Haematologica Oct 94(10):1336-8
249. Galili, N. Raza, A. Clinical implications of gene expression profiling in myelodysplastic syndromes: Recognition of ribosomal and translational gene dysregulation and development of predictive assays. Best Practice and Research Clinical Hematology 2009 22: 223-237
248. Naomi Galili, Ph.D., and Azra Raza, M.D. Pathogenesis and basic aspects of Myelydysplastic Syndromes. Hematology Education: The Educational program of the congress of The European Hematology Association 3(1): 2009.
247. Raza A, Galili N, Smith S, Godwin J, Lancet J, Melchert M, Jones M, Keck JG, Meng L, Brown GL, List A. Phase 1 multicenter dose-escalation study of ezatiostat hydrochloride (TLK199 tablets), a novel glutathione analog prodrug, in patients with myelodysplastic syndrome. Blood. 2009 Jun 25;113(26):6533-40. Epub 2009 Apr 27.
246. Raza A, Galili N, Callander N, Ochoa L, Piro L, Emanuel P, Williams S, Burris H 3rd, Faderl S, Estrov Z, Curtin P, Larson RA, Keck JG, Jones M, Meng L, Brown GL. Phase 1-2a multicenter dose-escalation study of ezatiostat hydrochloride liposomes for injection (Telintra(R), TLK199), a novel glutathione analog prodrug in patients with myelodysplastic syndrome. J Hematol Oncol. 2009 May 13;2:20.
245. Raza A, Jurcic JG, Roboz GJ, Maris M, Stephenson JJ, Wood BL, Feldman EJ, Galili N, Grove LE, Drachman JG, Sievers EL. Complete remissions observed in acute myeloid leukemia following prolonged exposure to lintuzumab: a phase 1 trial. Leuk Lymphoma. 2009 Jun 25:1-9. [Epub ahead of print]
244. Wang SA, Pozdnyakova O, Jorgensen JL, Medeiros LJ, Stachurski D, Anderson M, Raza A, Woda BA. Detection of paroxysmal nocturnal hemoglobinuria clones in patients with myelodysplastic syndromes and related bone marrow diseases, with emphasis on diagnostic pitfalls and caveats. Haematologica. 2008 Nov 10. [Epub ahead of print]. Haematologica.;94(1):29-37, 2009.
243. Benjamin L. Ebert, Naomi Galili, Pablo Tamayo, Jocelyn Bosco, Raymond Mak, Jennifer Pretz, Shyam Tanguturi, Christine Ladd-Acosta, Richard Stone, Todd R. Golub, Azra Raza. An Erythroid Differentiation Signature Predicts Response to Lenalidomide in Myelodysplastic Syndrome. PLoS Med 5(2): e35, 2008.
242. Sekeres MA, Maciejewski JP, Giagounidis AA, Wride K, Knight R, Raza A, List AF. Relationship of treatment-related cytopenias and response to lenalidomide in patients with lower-risk myelodysplastic syndromes. J Clin Oncol. 2008 Dec 0;26(36):5943-9.
241. Yue G, Hao S, Fadare O, Baker S, Pozdnyakova O, Galili N, Woda BA, Raza A, Wang SA. Hypocellularity in myelodysplastic syndrome is an independent factor which predicts a favorable outcome. Leuk Res. 2008 Apr;32(4):553-8. Epub 2007 Sep 20.
240. Raza A, Mehdi M, Mumtaz M, Ali F, Lascher S, Galili N. Combination of 5-azacytidine and thalidomide for the treatment of myelodysplastic syndromes and acute myeloid leukemia. Cancer. 2008 Oct 1;113(7):1596-604.
239. Wang SA, Tang G, Fadare O, Hao S, Raza A, Woda BA, Hasserjian RP. Erythroid-predominant myelodysplastic syndromes: enumeration of blasts from nonerythroid rather than total marrow cells provides superior risk stratification. Mod Pathol. 2008 Sep 12. [Epub ahead of print]
238. Pozdnyakova O, Miron PM, Tang G, Walter O, Raza A, Woda B, Wang SA. Cytogenetic abnormalities in a series of 1029 patients with primary myelodysplastic syndromes: a report from the US with a focus on some undefined single chromosomal abnormalities. Cancer. 2008 Nov 5. [Epub ahead of print]. Cancer. 2008 Dec 15;113(12):3331-40
237. Sekeres MA, Maciejewski JP, Giagounidis AA, Wride K, Knight R, Raza A, List AF. Relationship of Treatment-Related Cytopenias and Response to Lenalidomide in Patients With Lower-Risk Myelodysplastic Syndromes. J Clin Oncol. 2008 Dec 20;26(36):5943-9. J Clin Oncol. 2008 Nov 17. [Epub ahead of print]
236. Galili N, Devemy E, Raza A. Isolation of specific and biologically active peptides that bind cells from patients with acute myeloid leukemia (AML). J Hematol Oncol. 2008 Jul 10;1(1):8. [Epub ahead of print]
235. Wang, Sa; Tang, Guiling, Hao, Suyang; Raza, Azra; Woda, Bruce; Hasserjian, Robert. In Erythroid Predominant Myelodysplastic Syndrome How the Percentage of Myeloblasts Should be Enumerated? American J Clinical Pathology.
234. Yue G, Hao S, Fadare O, Baker S, Pozdnyakova O, Galili N, Woda BA, Raza A, Wang SA. Hypocellularity in myelodysplastic syndrome is an independent factor which predicts a favorable outcome. Leuk Res. 2008 Apr;32(4):553-8. Epub 2007 Sep 20.
233. Zota V, Miron PM, Woda BA, Raza A, Wang SA. Eosinophilia with FIP1L1-PDGFRA fusion in a patient with chronic myelomonocytic leukemia. J Clin Oncol. 2008 Apr 20;26(12):2040-1.
232. Benjamin L. Ebert, Jennifer Pretz, Jocelyn Bosco, Cindy Y. Chang, Pablo Tamayo, Naomi Galili, Azra Raza, David E. Root, Eyal Attar, Steven R. Ellis & Todd R. Golub Identification of RPS14 as a 5q- syndrome gene by RNA interference screen. Nature 2008 450: 335-340.
231. Ma X, Selvin S, Raza A, Foti K, Mayne ST. Clustering in the incidence of myelodysplastic syndromes. Leuk Res. 2007 Dec;31(12):1683-6. Epub 2007 May 15
230. Ma X, Does M, Raza A, Mayne ST. Myelodysplastic syndromes: incidence and survival in the United States. Cancer. 2007 Apr 15;109(8):1536-42.
229. Galili N, Cerny J, Raza A. Current treatment options: impact of cytogenetics on the course of myelodysplasia. Curr Treat Options Oncol. 2007 Apr;8(2):117-28.
228. Wang SA, Yue G, Hutchinson L, Landry ML, Hasserjian RP, Hao S, Galili N, Raza A, Woda BA. Myelodysplastic syndrome with pure red cell aplasia shows characteristic clinicopathological features and clonal T-cell expansion. Br J Haematol. 2007 Jul;138(2):271-5. Epub 2007 Jun 3
227. Stachurski D, Smith BR, Pozdnyakova O, Andersen M, Xiao Z, Raza A, Woda BA, Wang SA. Flow cytometric analysis of myelomonocytic cells by a pattern recognition approach is sensitive and specific in diagnosing myelodysplastic syndrome and related marrow diseases: Emphasis on a global evaluation and recognition of diagnostic pitfalls. Leuk Res. 2007 Jul 31 [Epub ahead of print] Leuk Res. 2008 Feb;32(2):215-24.
226. Neil E Kay, Tait D. Shanafelt, Ann K. Strege, Yean K. Lee, Nancy D. Bone, Azra Raza. Bone Biopsy Derived Marrow Stromal Elements Rescue CLL B-cells from Spontaneous and Drug Induced Cell Death and Facilitates an “Angiogenic Switch”. Leukemia Research, 2007 Jan 20; [Epub ahead of print]
225. Alan List 1, Gordon Dewald2, John Bennett3, Aristotle Giagounadis4, Azra Raza5, Eric Feldman6, Bayard Powell7, Peter Greenberg8, Deborah Thomas9, Richard Stone10, Craig Reeder11, Kenton Wride12, John Patin12, Michele Schmidt12, Jerome Zeldis12, and Robert Knight12 for the MDS-003 Study Investigators13 Hematologic and Cytogenetic Response to Lenalidomide in Myelodysplastic Syndrome with Chromosome 5q Deletion. N Engl J Med: 355:1456-65, 2006.
224. Azra Raza, James Reeves, Eric Feldman, Joachim Deeg, Luke Dreisbach, David Irwin, Charles A. Schiffer, Robert Knight, Jerome B. Zeldis, and Alan List. Efficacy of Lenalidomide in Transfusion-Dependent Myelodysplastic Syndromes Without Del(5q) Cytogenetic Abnormalities. Blood. 2008 Jan 1;111(1):86-93. Epub 2007 Sep 24.
223. Jan Markus , Matthew T. Garin , Juraj Bies, Naomi Galili, Azra Raza, Michael J.Thirman, Michelle M. Le Beau, Janet D.Rowley, P. Paul Liu, Linda Wolff Methylation-independent silencing of the tumor suppressor INK4B (p15) by CBFβ-SMMHC in acute myeloid leukemia with inv(16). Cancer Res. 2007 Feb 1;67(3):992-100.
222. Galili N, Ebert BL, Tamayo P, Bosco J, Mak R, Pretz J, Tanguturi S, Ladd-Acosta C, Stone R, Golub TR, Raza A. An erythroid differentiation signature predicts response to lenalidomide in myelodysplastic syndrome. PLoS Med. 2008 Feb;5(2):e35.
221. Pierre Fenaux, Azra Raza, Ghulam Mufti, Carlo Aul, Ulrich Germing, Hagop Kantarjian, Larry Cripe, René Kerstens, Peter De Porre, Razelle Kurzrock. A multicenter Phase 2 Study of the Farnesyltransferase Inhibitor Tipifarnib in Patients With Intermediate- to High-risk Myelodysplastic Syndrome. Blood. 2007 May 15;109(10):4158-63.
220. Mundle S and Raza A. Treatment of Myelodysplastic Syndromes with Exogenous Erythropoietin: A New Therapeutic Paradigm. Leukemia. 2006 Sep;20(9):1481-3.
219. Galili N, Mehdi M, Mumtaz M, Miron P, Woda B, Al-Homsi S, Westervelt P and Raza A. Roadmap for individualizing effective therapy in Myelodysplastic Syndromes Syndromes Future Oncology Jun;2(3):407-15. 2006.
218. Naomi Galili, Eric V. Sechman, Jan Cerny, Murtaza Medhi, Muhammad Mumtaz, and Azra Raza. Clinical response of myelodysplastic syndromes patients to treatment with coenzyme Q10. Leuk Res. 2007 Jan;31(1):19-26. Epub 2006 Oct 24.
217. Wang SA, Galili N, Cerny J, Sechman E, Chen SS, Loew J, Liu Q, Fadare O, Hasserjian R, Jones D, Qawi H, Woda B, Raza A. Chronic myelomonocytic leukemia evolving from preexisting myelodysplasia shares many features with de novo disease. Am J Clin Pathol. Nov;126(5):789-97, 2006.
216. Sa A. Wang, MD, Robert Hasserjian, MD, Jerome Loew, MD, Eric V. Sechman, Dan Jones, MD; Hao, Suyang, MD, Qin Liu, PhD, Murtaza Mehdi, MS, Naomi Galili, PhD, Bruce Woda, MD, Azra Raza, MD. Refractory anemia with ringed sideroblasts associated with marked thrombocytosis harbors JAK2 mutation and shows overlapping myeloproliferative and myelodysplastic features. Leukemia. Sep;20(9):1641-4, 2006.
215. Galili N, Raza A. Immune-modulatory drugs in myelodysplastic syndromes. Expert Opin Investig Drugs. Jul;15(7):805-13, 2006.
214. Naomi Galili, Murtaza Mehdi, Muhammad Mumtaz, Patricia Miron, Bruce Woda, Samer Al-Homsi, Peter Westervelt and Raza A. Can molecular profiling of cytogenetic subgroups draw a roadmap for individualizing therapy in myelodysplastic syndromes? Future Oncology Jun;2(3):407-15. 2006.
213. Kantarjian H, Issa JP, Rosenfeld CS, Bennett JM, Albitar M, DiPersio J, Raza A, Klimek V, Slack J, de Castro C, Ravandi F, Helmer III R, Shen L, Nimer SD, Leavitt R, Saba H. Decitabine Induces Hypomethylation and Improves Patient Outcomes in Myelodysplastic Syndromes: Results of a Phase III Randomized Study. Cancer. 2006 Apr 15;106(8):1794-803.
212. Galili N, Westervelt P, Raza A. MDS: The Therapeutic Landscape. Hospital Pharmacy, October 2005.
211. Raza A, Lisak L, Billmeier J, Pervaiz H, Mumtaz M, Gohar S, Wahid K, Galili N. Phase II Study of Topotecan and Thalidomide in Patients With High-Risk Myelodysplastic Syndromes. Leukemia and Lymphoma Mar 47(3): 433-440, 2006.
210. Raza A, Galili N. Lenalidomide for Myelodysplastic syndromes: finally, hope not hype. Nature Clinical Practice Oncology. Aug;2(8), 2005.
209. Candoni A, Raza A, Silvestri F, Lisak L, Galili N, Mumtaz M, Kikic F, Fanin R. Response rate and survival after thalidomide-based therapy in 248 patients with myelodysplastic syndromes. Ann Hematol. 2005 Jul;84(7):479-81. Epub Mar 31, 2005.
208. Raza A, Qawi H, Mehdi M, Mumtaz M, Galili N. Translational research in myelodysplastic syndromes. Rev Clin Exp Hematol. 2004 Dec 1;8(2):E2.
207. Raza A, Candoni A, Khan U, Lisak L, Tahir S, Silvestri F, Billmeier J, Alvi MI, Mumtaz M, Gezer S, Venugopal P, Reddy P, Galili N: Remicade as TNF suppressor in patients with myelodysplastic syndrome. Leukemia and Lymphoma 2004 Oct 45(10) 2099-2104
206. Raza A: Roots of Cancer: Changing physical space as a consequence of aging, monoclonal expansion and critical state universality. Submitted to Leukemia and Lymphoma, 2004.
205. Candoni A, Silvestri F, Buonamici S, Li, D, Reddy PL, Galili N, Nucifora G, Raza A: “Targeted Therapies in Myelodysplastic Syndromes”: Semin Hematol. Apr;41(2 Suppl 4):13-20, 2004.
204. Saberwal G, Lucas S, Janssen I, Deobhakta A, Hu WY, Galili N, Raza A, Mundle SD: Increased levels and activity of E2F1 transcription factor in myelodysplastic syndromes. Int. J.Hematol.Aug;80(2):146-54,2004.
203. Raza A, Buonamici S, Lisak L, Tahir S, Donglan L, Imran M, Chaudary NI, Pervaiz H, Gallegos JA, Alvi MI, Mumtaz M, Gezer S, Venugopal P, Reddy P, Galili N, Candoni A, Singer J, Nucifora G: Arsenic trioxide and thalidomide combination produces multi-lineage hematologic responses in myelodysplastic syndromes patients, particularly in those with high pre-therapy EV11 expression. Leuk Res Aug;28(8):791-803, 2004.
202. Raza A: Evolving targeted therapies in myelodysplastic syndromes. Indian J. Hemat & Blood Transf. Vol XXI: suppl 3:137-139, 2003.
201. Saberwal G, Broderick, E, Janssen I, Shetty V, Alvi S, Lisak L, Venugopal P, Raza A, Mundle SD: Involvement of cyclin D1 and E2F1 in intramedullary apoptosis in Myelodysplastic Syndromes. J Hematother Stem Cell Res 12(4):443-450, 2003.
200. Huang XK, Meyer P, Li B, Raza A, Preisler HD: The effects of the farnesyl transferase inhibitor FTI L –778,123 on Normal, Myelodysplastic, and Myeloid Leukemia Bone Marrow Progenitor proliferation in vitro. Leukemia and Lymphoma 44(1):157-164, 2003.
199. Gladstone B, Sivaraman S, Galili N, Venugopal P, Janssen I, Nayini J, Yang J, Hsu WT, Raza A, Preisler HD: A novel method for single cell detection of in situ telomerase or histone H3 in combination with clonal analysis by FISH. Leukemia Research 27:529-537, 2003.
198. Reddy P, Raza A: Response to increased incidence of mitochondrial cytochrome c-oxidase gene mutations in patients with myelodysplastic syndromes. British Journal of Haematology, 119:1139-1140, 2002.
197. Allampallam K, Shetty V, Mundle S, Dutt D, Kravitz H, Reddy PL, Alvi S, Galili N, Saberwal GS, Anthwal S, Shaikh M, York A, Raza A: Biologic Significance of proliferation, apoptosis, cytokines, and monocyte/macrophage cells in bone marrow biopsies of 145 patients with myelodysplastic syndrome. International Journal of Hematology 75:289-297, 2002.
196. Reddy PL, Shetty VT, Dutt D, York A, Dar S, Mundle SD, Allampallam K, Alvi S, Galili N, Saberwal GS, Anthwal S, Shaikh M, SulemanS, Kamal SY, Raza A: Increased incidence of mitochondrial cytochrome c-oxidase gene mutations in patients with myelodysplastic syndromes. British Journal of Haematology 116:564-575, 2002.
195. Hu Z, Gomes I, Horrigan S, Kravarusic J, Mar B, Arbieva Z, Chyna B, Fulton N, Edassery S, Raza A, Westbrook CA: A novel nuclear protein, 5qNCA (LOC51780) is a candidate for the myeloid leukemia tumor suppressor gene on chromosome 5 band q31. Oncogene 20:6946-6954, 2001.
194. Mundle SD, Raza A: Defining dynamics of self-assembled Fas receptor activation. Trends in Immunology 23(4):187-194, 2002.
193. Shetty V, Hussaini S, Alvi S, Joshi L, Shaher A, Dangerfield B, Nascimben F, Mundle S, Allampallam K, Reddy P, Galili N, Raza A: Excessive apoptosis, increased phagocytosis, nuclear inclusion bodies and cylindrical confronting cisternae in bone marrow biopsies of myelodysplastic syndrome patients. British Journal of Haematology 116:817-825, 2002.
192. Preisler HD, Li B, Chen H, Fisher L, Nayini J, Raza A, Creech S, Venugopal P. P15INK4B gene methylation and expression in normal, myelodysplastic and acute myelogenous leukemia cells. Leukemia 15:1589-1595, 2001.
191. Zorat F, Shetty V, Dutt D, Lisak L, Nascimben F, Allampallam K, Dar S, York A, Gezer S, Venugopal P, Raza A: The clinical and biologic effects of thalidomide in patients with myelodysplastic syndromes. British Journal of Haematology 115:881-894, 2001.
190. Alvi S, Shaher A, Shetty V, Henderson B, Dangerfield B, Zorat F, Joshi L, Anthwal S, Lisak L, Little L, Gezer S, Mundle S, Reddy PL, Allampallam K, Huang X, Galili N, Borok RZ, Raza A: Successful establishment of long term bone marrow cultures in 103 patients with myelodysplastic syndromes. Leukemia Research 25:941-954, 2001.
189. Shetty V, Mundle S, Raza A: Pseudo Pelger-Huet anomaly in MDS – Hyposegmented or apoptotic neutrophil? Blood 98(4):1273-1275, 2001.
188. Raza A, Meyer P, Dutt D, Zorat F, Lisak L, Nascimben F, du Randt M, Kaspar C, Goldberg C, Loew J, Dar S, Gezer S, Venugopal P, Zeldis J: Thalidomide produces transfusion independence in long standing refractory anemias of patients with myelodysplastic syndromes. Blood 98(4):958-965, 2001.
187. Raza A: Improve or abandon the standardized response criteria for myelodysplastic syndromes recommended by the International Working Group. Blood 98(1):251-252, 2001.
186. Mundle S, Allampallam K, Rashid KA, Dangerfield B, Cartlidge J, Zeitler D, Afenya E, Alvi S, Shetty V, Venugopal P, Raza A: Presence of activation related m-RNA for EBV and CMV in the bone marrow of patients with myelodysplastic syndromes. Cancer Letters 164:197-205, 2001.
185. Raza A: What the Human Genome Project will not tell us: the role of microorganism in disease. Leukemia Research 25:179-181, 2001.
184. Raza A, Qawi H, Andric T, Dar S, Lisak L, Huang R-W, Venugopal P, Gezer S, Gregory SA, Hsu W-T, Loew J, Robin E, Rifkin S, Shah R, Divgi A, Taylor R, Grosset A: Pentoxifylline, Ciprofloxacin and dexamethasone improve the ineffective hematopoiesis in myelodysplastic syndrome patients. Hematology (5):275-284,2000.
183. Mundle SD, Shetty V, Raza A: Caspases and apoptosis in myelodysplastic syndromes. Experimental Hematology 28:1310-1314, 2000.
182. Bi S, Gao X, Devemy E, Chopra H, Venugopal P, Raza A, Preisler HD: Cytokine production by in vitro processed and unprocessed hematopoietic cells. Cytokine 12(7):1124-1128, 2000.
181. Li B, Yang J, Andrews C, Chen YX, Toofanfard P, Huang RW, Horvath E, Chopra H, Raza A, Preisler HD: Telomerase activity in preleukemia and acute myelogenous leukemia. Leuk Lymphoma 36(5-6):579-87, 2000.
180. Raza A: Myelodysplastic syndromes may have an infectious etiology. Journal of Toxicology and Environmental Health, Part A, 61:387-390, 2000.
179. Allampallam K, Dutt D, Nair C, Shetty V, Mundle S, Lisak L, Andrews C, Ahmed B, Mazzone L, Zorat F, Borok R, Muzammil M, Gundroo A, Ansaarie I, Raza A: The clinical and biologic significance of abnormal lipid profiles in patients with myelodysplastic syndromes. J Hematother Stem Cell Res 9(2):247-255, 2000.
178. Westbrook CA, Hsu W-T, Chyna B, Litvak D, Raza A, Horrigan SK: Cytogenetic and molecular diagnosis of chromosome 5 deletions in myelodysplasia. Br J Haematol 110(4):847-855, 2000.
177. Shetty V, Hussaini S, Broady-Robinson L, Allampallam K, Mundle S, Borok R, Cartlidge J, Broderick E, Mazzoran L, Zorat F, Raza A: Intramedullary apoptosis of hematopoietic cells in myelodysplastic syndrome patients can be massive: apoptotic cells recovered from high density fraction of bone marrow aspirates. Blood 96(4):1388-1392, 2000.
176. Mundle SD, Mativi BY, Cartlidge JD, Dangerfield B, Broady-Robinson L, Li B, Shetty V, Venugopal P, Gregory SA, Preilser HD, Raza A: Signal antonymy unique to myelodysplastic marrows correlates with altered expression of E2F1. Br J Haematol 109(2):376-381, 2000.
175. Raza A: Anti-TNF therapies in Rheumatoid Arthritis, Crohn’s Disease, Sepsis and Myelodysplastic Syndromes. Microsc Res Tech 50(3):229-235, 2000.
174. Raza A, Qawi H, Lisak L, Andric T, Dar S, Andrews C, Venugopal P, Gezer S, Gregory S, Loew J, Robin E, Rifkin S, Hsu W-T, Huang R-W. Patients with myelodysplastic syndromes benefit from palliative therapy with amifostine, pentoxyfylline, and ciprofloxacin with or without dexamethasone. Blood 95(5):1580-1587, 2000.
173. Raza A: Consilence across evolving dysplasias affecting myeloid, cervical, esophageal, gastric and liver cells: Common themes and emerging patterns. Leukemia Research 24(1):63-72, 2000.
172. Allampallam K, Shetty V, Hussaini S, Mazzoran L, Zorat F, Huang R, Raza A: Measurement of mRNA expression for a variety of cytokines and its receptors in bone marrows of patients with myelodysplastic syndromes. Anticancer Res 19(6B):5323-5328, 1999.
171. Preisler HD, Gao X-Z, Ming T, Li B, Bi S, Devemy E, Loew J, Raza A: Marrow cytokine transcripts and the secondary hematologic disorders. Leukemia and Lymphoma 35(3-4):297-302, 1999.
170. Shetty V, Allampallam K, Raza A: Increased macrophages, high serum M-CSF and low serum cholesterol in myelodysplasia and Kawasaki Disease. Br J Haematol 106(4):1068-1070, 1999.
169. Mundle SD, Mativi Y, Bagai K, Feldman G, Cheema P, Gautam U, Reza S, Cartlidge JD, Venugopal P, Shetty V, Gregory SA, Robin E, Rifkin S, Shah R, Raza A: Spontaneous down-regulation of fas-associated phosphatase-1 (FAP-1) may contribute to the excessive apoptosis in myelodysplastic marrows. Int J Hematol 70(2):83-90, 1999.
168. Ali A, Mundle S, Ragasa D, Reza S, Shetty V, Mativi BY, Cartlidge J, Azharuddin M, Qawi H, Dar S, Raza A: Sequential activation of caspase-1 and caspase-3-like proteases during apoptosis in myelodysplastic syndromes. J Hematother Stem Cell Res 8(4):343-356, 1999.
167. Mundle SD, Reza S, Ali A, Mativi BY, Shetty V, Venugopal P, Gregory SA, Raza A: Correlation of tumor necrosis factor α (TNFα) with high caspase 3-like activity in myelodysplastic syndromes. Cancer Lett 140(1-2):201-207, 1999.
166. Huang XK, Gao XZ, Leurgans S, Chen S, Loew J, Toofanfard P, Raza A, Preisler HD: Proliferation of myelodysplastic progenitor cells in vitro: Effects of different in vitro conditions. Cancer Research Therapy and Control, 7: 295-309, 1999.
165. Reza S, Dar S, Andric T, Qawi H, Mundle S, Shetty V, Venugopal P, Ali I, Lisak L, Raza A: Biologic characteristics of 164 patients with myelodysplastic syndromes. Leuk Lymphoma 33(3-4):281-287, 1999.
164. Mundle S, Venugopal P, Shetty V, Ali A, Chopra H, Handa H, Rose S, Mativi BY, Gregory SA, Preisler HD, Raza A: The relative extent and propensity of CD34+ vs. CD34- cells to undergo apoptosis in myelodysplastic marrows. Int J Hematol 69(3):152-159, 1999.
163. Goyal R, Qawi H, Ali I, Dar S, Mundle S, Shetty V, Mativi Y, Allampallam K, Lisak L, Loew J, Venugopal P, Gezer S, Robin E, Rifkin S, Raza A: Biological characteristics of patients with hypocellular myelodysplastic syndromes. Leuk Res 23(4):357-364, 1999.
162. Dar S, Mundle S, Andric T, Qawi H, Shetty V, Reza S, Mativi BY, Allampallam K, Ali A, Venugopal P, Gezer S, Broady-Robinson L, Cartlidge J, Showel M, Hussaini S, Ragasa D, Ali I, Chaudhry A, Waggoner S, Lisak L, Raza A: Biological characteristics of myelodysplastic syndrome patients who demonstrated high versus no intramedullary apoptosis. Eur J Haematol: 62(2):90-94, 1999.
161. Parcharidou A, Raza A, Economopoulos T, Papageorgiou E, Anagnostou D, Papadaki T, Raptis S: Extensive apoptosis of bone marrow cells as evaluated by in the in-situ end labeling (ISEL) technique may be the basis for ineffective hematopoiesis in patients with myelodysplastic syndromes. Eur J Haematol 62(1):19-26, 1999.
160. Mundle SD, Ali A, Cartlidge J, Reza S, Alvi S, Showel M, Mativi Y, Shetty V, Venugopal P, Gregory SA, Raza A: Evidence for involvement of tumor necrosis factor-α in apoptotic death of bone marrow cells in myelodysplastic syndromes. Am J Hematol 60(1):36-47, 1999.
159. Preisler HD, Gao X-Z, Bi S, Devemy E, Loew, Raza A: Marrow cytokine transcripts and the secondary hematologic disorders. Leuk Lymphoma 35(3-4):297-302, 1999.
158. Preisler HD, Raza A: The relationship between tumor proliferation and the response of malignant disease to cytotoxic therapy: Some lessons learned from Cell Cycle Studies. Cancer Research therapy and Control:5:171-180, 1998.
157. Span LFR, Dar SE, Shetty V, Mundle SD, Broady-Robinson L, Alvi S, Raymakers RAP, Witte T de, Raza A: Apparent expansion of CD34+ cells during the evolution of myelodysplastic syndromes to acute myeloid leukemia. Leukemia 12(11):1685-1695, 1998.
156. Raza A: Hypothesis: Myelodysplastic syndromes may have a viral etiology. Int J Hematol 68(3):245-256, 1998.
155. Reza S, Shetty V, Dar S, Qawi H, Raza A: Tumor necrosis factor alpha levels decrease with anti-cytokine therapy in patients with myelodysplastic syndromes. J Interferon Cytokine Res 18(10):871-877, 1998.
154. Raza A: The initial transforming event in myelodysplastic syndromes may be viral: the case for cytomegalovirus. Med Oncol 15(3):165-173, 1998.
153. Mundle SD, Shetty V, Raza A: Is excessive spontaneous intramedullary apoptosis unique to myelodysplasia. Exp Hematol 26(11):1014-1017, 1998.
152. Handa H, Hegde UP, Kotelnikov, VM, Mundle SD, Dong L-M, Hsu W-T, Burke P, Rose S, Gaskin F, Raza A, Preisler HD: The effect of 13-cis Retinoic Acid and Interferon-α in chronic myelogenous leukemia in vivo in patients. Leuk Res 21(11/12):1087-1096, 1997.
151. Raza A, Alvi S, Borok RZ, Span L, Parcharidou A, Alston D, Rifkin S, Robin E, Shah R, Gregory SA: Excessive proliferation matched by excessive apoptosis in myelodysplastic syndromes: The cause-effect relationship. Leuk Lymphoma 27(1-2):111-118, 1997.
150. Handa H, Hegde UP, Kotelnikov, VM, Mundle SD, Dong L-M, Burke P, Rose S, Gaskin F, Raza A, Preisler HD: Bcl-2 and c-myc expression, cell cycle kinetics and apoptosis during the progression of chronic myelogeneous leukemia from diagnosis to blastic phase. Leuk Res 21(6):479-489, 1997.
149. Preisler HD, Raza A, Bonomi P, Taylor S, LaFolett S, Leslie W, Lincoln S: Regrowth resistance as a likely significant contributor to treatment failure in drug-sensitive neoplastic diseases. Cancer Invest 15(4):358-368, 1997.
148. Preisler HD, Bi S, Venugopal P, Raza A: Cytokines, Molecular biologic abnormalities and Acute Myelogenous Leukemia. Leuk Res 21(4):299-312, 1997.
147. Raza A, Alvi S, Broady-Robinson L, Showel M, Cartlidge J, Mundle SD, Shetty V, Borok RZ, Dar SE, Chopra HK, Span L, Parcharidou A, Hines C, Gezer S, Venugopal P, Loew J, Showel J, Alston D, Hernandez B, Rifkin S, Robin E, Shah R, Gregory S: Cell cycle kinetic studies in 68 patients with myelodysplastic syndromes following intravenous iodo- and/or bromodeoxyuridine. Exp Hematol 25(6):530-535, 1997.
146. Shetty V, Mundle S, Alvi S, Showel M, Broady-Robinson L, Dar S, Borok R, Showel J, Gregory S, Rifkin S, Gezer S, Parcharidou A, Venugopal P, Shah R, Hernandez B, Klein M, Alston D, Robin E, Dominquez C, Raza A: Measurement of apoptosis, proliferation and three cytokines in 46 patients with myelodysplastic syndromes. Leuk Res 20(11/12):891-900, 1996.
145. Raza A, Gregory SA, Preisler HD: The Myelodysplastic syndromes in 1996: Complex stem cell disorders confounded by dual actions of cytokines. Leuk Res 20(11/12):881-890, 1996.
144. Mundle S, Gregory SA, Preisler HD, Raza A: Enzymatic programming of apoptotic cell death. Pathobiology 64(3):161-170, 1996.
143. Raza A, Mundle S, Shetty V, Alvi S, Chopra H, Span L, Parcharidou A, Dar S, Venugopal P, Borok R, Gezer S, Showel J, Loew J, Robin E, Rifkin S, Alston D, Hernandez B, Shah R, Kaizer H, Gregory S: A paradigm shift in myelodysplastic syndromes. Leukemia 10(10):1648-1652, 1996.
142. Mundle SD, Venugopal P, Pandav DV, Broady-Robinson L, Gezer S, Robin EL, Rifkin SR, Klein M, Alston DE, Hernandez BM, Rosi D, Alvi S, Shetty VT, Gregory SA, Raza A: Indication of an involvement of interleukin-1ß converting enzyme (ICE)-like protease in intramedullary apoptotic cell death in the bone marrows of patients with myelodysplastic syndromes (MDS). Blood 88(7):2640-2647, 1996.
141. Mundle S, Kotelnikov VM, Wood NB, Coon JS, Horvath E, Taylor SG, LaFollette S, Caldarelli DD, Hutchinson JC, Panje WR, Preisler HD, Raza A: Assessment of apoptosis in relation to proliferation and mutational status of p53 gene in head and neck cancers. International Journal of Oncology 8:1257-1264, 1996.
140. Raza A, Mundle S, Shetty V, Alvi S, Chopra H, Dar S, Venugopal P, Borok R, Gezer S, Showel J, Robin E, Rifkin S, Alston D, Hernandez B, Gregory S: Novel insights into the biology of Myelodysplastic Syndromes: Excessive apoptosis and the role of cytokines. Int J Hematol 63(4):265-278, 1996.
139. Uhal BD, Joshi I, True AL, Mundle S, Raza A, Pardo A, Selman M: Fibroblasts isolated after fibrotic lung injury induce apoptosis of alveolar epithelial cells in vitro. Am J Physiol 269(Lung Cell Mol Physiol 13):L819-L828, 1995.
138. Preisler HD, Raza A, Gopal V, Bokhari SAJ: Distribution of Cell cycle Times Among the Leukemia Cells Within Individual Patients with Acute Myelogenous Leukemia. Leuk Res 19(10):693-698, 1995.
137. Mundle SD, Gao XZ, Khan S, Gregory SA, Preisler HD, Raza A: Two in situ labeling techniques reveal different patterns of DNA fragmentation during spontaneous apoptosis in vivo and induced apoptosis in vitro. Anticancer Res 15(5B):1895-1904, 1995.
136. Shetty V, Mundle S, Sanoy A, Sanghvi R, Loew J, Marcus B, Showel J, Gregory S, Raza A: A multivariate study of non-Hodgkin’s lymphoma involving proliferation, apoptosis, bcl-2 and the microenvironment. Leuk Lymphoma 18(3-4):273-279, 1995.
135. Raza A, Gezer S, Mundle S, Gao X-Z, Alvi S, Borok R, Rifkin S, Iftikhar A, Shetty V, Parcharidou A, Loew J, Marcus B, Khan Z, Chaney C, Showel J, Gregory S, Preisler H: Apoptosis in bone marrow biopsy samples involving stromal and hematopoietic cells in 50 patients with myelodysplastic syndromes. Blood 86(1):268-276, 1995.
134. Mundle S, Raza A: The two in situ techniques do not differentiate between apoptosis and necrosis but rather reveal distinct patterns of DNA fragmentation in apoptosis. [Correspondence], Lab Invest 72(5):611-613, 1995.
133. Raza A, Mundle S, Iftikhar A, Gregory S, Marcus B, Khan Z, Alvi S, Shetty V, Dameron S, Wright V, Adler S, Loew J, Schott S, Ali N, Preisler H: Simultaneous assessment of cell kinetics and programmed cell death in bone marrow biopsies of myelodysplastics reveals extensive apoptosis as the probable basis for ineffective hematopoiesis. Am J Hematol 48(3):143-154, 1995.
132. Preisler HD, Banavali SD, Yin M, Gopal V, Li YW, Gaskin F, Raza A: Parallel studies of clonogenic leukemia cells and of the leukemia cell population as a whole in acute myelogenous leukemia. Eur J Cancer 30A(10):1511-1516, 1994.
131. Preisler HD, Raza A, Larson R, Goldberg J, Tricot G, Browman G, Bennett J: The relationship of the in vivo cell cycle characteristics and treatment outcome in acute myelogenous leukemia to the expression of the FMS, and MYC proto-oncogenes. Leuk Lymphoma 14(3-4):273-278, 1994.
130. Mundle S, Iftikhar A, Shetty V, Dameron S, Wright-Quinones V, Marcus B, Loew J, Gregory S, Raza A: Novel in situ double-labeling for simultaneous detection of proliferation and apoptosis. J Histochem Cytochem 42(12); 1533-1537, 1994.
129. Mundle S, Iftikhar A, Shetty V, Alvi S, Dameron S, Gregory S, Marcus B, Khan S, Raza A: In Situ End Labeling of DNA to detect apoptotic cell death in a variety of human tumors. Cell Death and Differentiation 1:117-122, 1994.
128. Kadam P, Masterson M, Soukup S, Moore C, Raza A, Lampkin BC: Detection of unexpected clones of monosomy 7 in childhood acute lymphoblastic leukemia using fluorescence in situ hybridization. Anticancer Res 14(2A):545-548, 1994.
127. Preisler HD, Raza A, Gopal V, Banavali SD, Bokhari SAJ, Lampkin B: The study of acute leukemia cells by means of acridine orange staining and flow cytometry. Leuk Lymphoma 13(1-2):61-73, 1994.
126. Goldberg J, Raza A, Gryn H, Bennett J, Browman G, Bryant J, Grunwald H, Larson R, Vogler R, Preisler HD: Mitoxantrone and 5-Azacytidine for refractory/relapsed ANLL or CML in blast crisis. A Leukemia Intergroup Study. Am J Hematol 43(4):286-290, 1993.
125. Preisler HD, Raza A, Baccarani M: Proliferative advantage rather than classical drug resistance as the cause of treatment failure in chronic myelogenous leukemia. Leuk Lymphoma 11(Suppl 1):303-306, 1993.
124. Preisler HD, Raza A: An overview of some studies of chronic myelogenous leukemia: Biological-clinical observations and viewing the disease as a chaotic system. Leuk Lymphoma 11(Suppl 1):145-150, 1993.
123. Preisler HD, Larson R, Banavali S, Yin M, Li YQ, Banerjee M, Gopal V, Raza A: Effects of rhGM-CSF on myeloid clonogenic cells in acute myelogenous leukemia patients. Leuk Lymphoma 10(3):183-186, 1993.
122. Raza A, Preisler HD, Browman GP, Larson RA, Rustum Y, Goldberg J, Vogler R, Miller KA, Bennett J, Kukla C: Long term outcome of patients with acute myelogenous leukemia (AML): The role of maintenance therapy, consolidation therapy and the predictive value two in vitro assays. Leuk Lymphoma 10(1-2):57-66, 1993.
121. Banavali S, Pancoast JR, Tricot G, Larson R, Goldberg J, Raza A, Bismayer J, Preisler H. Serial studies of MYC expressions in bone marrow biopsies: effects of cytotoxic agents, rh-GMCSF and retinoic acid-α-interferon. Eur J Cancer 29A(8):1162-1167, 1993.
120. Preisler HD, Raza A, Sigmund D, Gopal V: Poor prognosis in acute myelogenous leukemia. Leukemia & Lymphoma 9:273-283, 1993.
119. Preisler HD, Raza A: Can regrowth resistance be stopped? Contemporary Oncology, 3(5):12-23, 1993.
118. Kadam P, Umerani A, Srivastava A, Masterson M, Lampkin B, Raza A: Combination of classical and interphase cytogenetics to investigate the biology of myeloid disorders: Detection of masked monosomy 7 in AML. Leuk Res 17(4):365-374, 1993.
117. Raza A, Preisler H, Lampkin B, Lykins J, Kukla C, Gartside P, Sheikh Y, Yousuf N, White M, Barcos M, Bennett J, Browman G, Goldberg J, Grunwald H, Larson R, Vardiman J, Vogler R: Clinical and prognostic significance of in vivo differentiation in acute myeloid leukemia. Am J Hematol, 42(2):147-157, 1993.
116. Raza A, Preisler HD, Li YQ, Larson R, Goldberg J, Browman G, Bennett J, Grunwald H, Vogler R, Kukla C: Biological characteristics of newly diagnosed poor prognosis acute myelogenous leukemia. Am J Hematol, 42 (4): 359-366, April 1993.
115. Raza A, Yousuf N, Bokhari SAJ, Abbas A, Raza A, Lampkin B, Pancoast J, Bismayer J, Siegrist C, Browman G, Bennett J, Goldberg J, Grunwald H, Larson R, Tricot G, Vogler R, Gartside P, Preisler H. Cell cycle characteristics: Alterable determinants of remission duration in a study of 179 standard risk newly diagnosed patients with acute myeloid leukemia. International Journal of Oncology, 2: 301-307, 1993.
114. Preisler HD, Raza A, Hegde UP: Prognostic factors and treatment outcome in acute myelogenous leukemia. Proceedings of the Second Farmitalia Carlo Erba Symposium, Genoa in Acute Leukemias and Chronic Myelogenous Leukemia: New Developments, pp 25-31, 1993.
113. Raza A, Shetty V, Mundle S, Budev A, Dameron S, Alvi S, Saeed S, Preisler HD: Methodological constraints placed on cell cycle studies if they are to be accurate and clinically relevant. Proceedings of the Second Farmitalia Carlo Erba Symposium, Genoa in Acute Leukemias and Chronic Myelogenous Leukemia: New Developments, pp 21-24, 1993.
112. Raza A, Preisler HD, Lampkin B, Bennett J: High expression of transforming growth factor-ß long cell cycle times and a unique clustering of S-phase cells in patients with acute promyelocytic leukemia. Blood, Letter (response), 80 (12): 3256-3257, 1992.
111. Raza A, Yousuf N, Abbas A, Umerani A, Mehdi A, Bokhari SAJ, Sheikh Y, Qadir K, Freeman J, Masterson M, Miller MA, Lampkin B, Browman G, Bennett J, Goldberg J, Grunwald H, Larson R, Vogler R, Preisler H: High expression of transforming growth factor-ß long cell cycle times and a unique clustering of S-phase cells in patients with acute promyelocytic leukemia. Blood, 79(4):1037-1048, 1992.
110. Gopal V, Hulette B, Li YQ, Kuvelkar R, Raza A, Larson R, Goldberg J, Tricot G, Bennet J, Preisler HD: c-myc an c-myb Expression in Acute Myelogenous Leukemia. Leuk Res 16(10):1003-1011, 1992.
109. Preisler HD, Raza A: Cell cycle studies in acute myelogenous leukemia. Leukemia 6(8):751-753, 1992.
108. Masterson M, Lampkin B, Yousuf N, Sheikh Y, Raza A: In vivo cell cycle characteristics of pediatric leukemia patients. Exp Hematol, 20(10):1184-1187, 1992.
107. Preisler HD, Raza A, Larson RA: Alteration of the proliferative rate of acute myelogenous leukemia cells in vivo in patients. Blood 80(10):2600-2603, 1992.
106. Raza A, Mazewski C, Lampkin B, Masterson M, Umerani A, Mehdi A, Bokhari SAJ, Qadir K, Yousuf N, Kadam P and Preisler HD: Properties of leukemia cells need to be assessed simultaneously with the microenvironment: Critical need for examining bone marrow biopsies in acute myeloid leukemia. Tata Memorial Cancer Center Jubilee Celebration publication, Jan 1992.
105. Preisler HD, Raza A: Current Problems in the treatment of acute myelocyte leukemia (AML) and some possible solutions. 5th International Symposium on Therapy of Acute Leukemias. Leukemia (Supplement), 6(2):81-84, 1992.
104. Preisler H, Raza A: Problems associated with the study of cytokines in patients with leukemia. Eur J Cancer 28A (6/7):1293, 1992.
103. Preisler HD, Raza A: Assessment of cell cycle effects of cytokines in vivo. Letter-to-the-Editor, J Clin Oncol 10 (4):673-674, 1992.
102. Chughtai S, Mehdi A, Umerani A, Qadir K, Bokhari SAJ, Yousuf N, Raza A. Presence of transforming growth factor beta in the hematopoietic microenvironment: Clinical, prognostic and biological implications. Clinical Biotechnology 4(1):11-16, 1992.
101. Mehdi SA, Bokhari SAJ, and Raza A: A novel triple label method validates the double label technique of defining cell cycle kinetics in HL-60 cells. Anticancer Res 12:1443-1446, 1992.
100. Qadir K, Bokhari SAJ, Miller MA, Siegrist C, Bismayer J and Raza A: In situ localization of transforming growth factor-beta and S-phase cells in patients with acute myeloid leukemia and myelodysplastic syndrome. Anticancer Res 12(2):403-407, 1992.
99. Bokhari SAJ, Abbas A, Yousuf N, Mehdi A, Umerani A, Qadir K, Sheikh Y, Akhtar S, Chugtai S, Raza A: Cell cycle parameters as biological predictors of prognosis in AML: A review and update on cell cycle kinetics and remission induction/duration. Leukemia and Lymphoma, 6(3):197-208, 1992.
98. Raza A, Yousuf N, Umerani A, Mehdi A, Bokhari SAJ, Sheikh Y, Qadir K, Masterson M, Milker MA, Lampkin B, Browman G, Bennett J, Goldberg J and Preisler H: High expression of TGF-β, long cell cycle times and a unique clustering of S-phase cells in patients with acute promyelocytic leukemia. Blood, 79(4):1037-1048, 1992.
97. Larson RA, Day R, Azarnia N, Bennettt J, Browman G, Goldberg J, Gottlieb A, Grunwald H, Miller K, Raza A, Vogler R, Winton E, Preisler HD: The selective use of AMSA following high-dose cytarabine in patients with acute myeloid leukemia in relapse. In Press. Br J Haematol: 82(2):337-346, 1992.
96. Raza A, Yousuf N, Bokhari SAJ, Sheikh Y, Akhtar S, Chughtai S, Umerani A, Mehdi SA, Miller MA, Masterson M, Lampkin B: In situ cell cycle kinetics in bone marrow biopsies following sequential infusions of IUdR/BrdU in patients with hematopoietic malignancies. Leuk Res 16(3):299-306, 1992.
95. Miller MA, Bokhari SAJ, Qadir K, Raza A: Simultaneous assessment of TGF-β and cell cycle kinetics using IUdR/BrdU infusions in human neoplasms from plastic embedded tissue. J Histochem Cytochem 40(3):427-430, 1992.
94. Bokhari SAJ, Raza A: A novel mathematical derivation of total cell cycle time in malignant cells using two DNA-specific probes in vivo Cytometry 13(2):144-148, 1992.
93. Yanik G, Yousuf N, Miller M, Swerdlow S, Meyer J, Lampkin B and Raza A: In vivo determination of cell cycle kinetics in lymphomas and lymph node biopsies using iododeoxyuridine and bromodeoxyuridine. J Histochm Cytochem 40(5):723-728, 1992.
92. Preisler HD and Raza A: The role of emerging technologies in the diagnosis and staging of neoplastic disease. Cancer 69(6):1520-1526, 1992.
91. Raza A, Gezer S, Anderson J, Lykins J, Bennett J, Browman G, Goldberg J, Gottlieb A, Grunwald H, Larson R, Miller K, Vogler R, Verkh, Preisler HD: Relationship of 3HaraC incorporation and response to therapy with HDaraC in AML patients. A Leukemia Intergroup Study. Exp Hematol, 20(10):1194-1200, 1992.
90. Raza A, Yousuf N, Bokhari SAJ, Mehdi A, Masterson M, Lampkin B, Yanik G, Mazewski C, Khan S, Preisler HD: Contribution of in vivo proliferation/differentiation studies towards the development of a combined functional and morphologic system of classification of neoplastic disease. Cancer (Suppl) 69(6):1557-1566, 1992.
89. Gao XZ, Yin M, Wang Z, Raza A, Preisler HD: Effects of rhGM-CSF on leukemia cell proliferation and on the incorporation of cytosine arabinoside into DNA. Cell Biochem Funct 9(3):155-161, 1991.
88. Preisler HD, Raza A, Kukla C, Larson R, Goldberg J and Browman G: ILIB expression and treatment outcome in acute myelogenous leukemia (AML). Blood 78(3):849-850, 1991.
87. Yousuf N, Khan S, Sheikh Y, Hyams D, Bokhari J, Raza A: Cell cycle parameters and DNA ploidy in Colorectal Carcinomas. J Surg Res 51(6):457-462, 1991.
86. Preisler H, Raza A, Hewlett B, Silvestri F, Li YQ, Banavali SD, Venugopal P: The use of biologically active agents in the treatment of AML and other neoplastic diseases. Status of Differentiation Therapy (2):379-386, 1991.
85. Preisler H, Larson R, Raza A, Browman G, Goldberg J, Vogler R, Day R, Gottlieb A, Vardiman J, Bennett J, Kukla C and Grunwald H: The treatment of patients with newly diagnosed poor prognosis acute myelogenous leukemia: response to treatment and treatment failure. Br J Haematol, 79:390-397, 1991.
84. Preisler H, Raza A, Larson R, Godberg J, Ticot G, Carey M, Kukla C: Some reasons for the lack of progress in the treatment of acute myelogenous leukemia: A review of three consecutive trials of the treatment of poor prognosis patients. Leuk Res 15 (9):773-780, 1991.
83. Raza A, Yousuf N, Bokhari J, Guo WJ, White M, Sheikh Y, Mehdi Am Umerani A, Chughtai S and Preisler H: Detection of in vivo differentiation in “high risk” and “standard risk” newly diagnosed patients with acute myeloid leukemia. Status of Differentiation Therapy (2):415-421, 1991.
82. Raza A, Bokahari J, Yousuf N, Mehdi A, Mazewski C, Khan S, Baker V, Lampkin B: Cell cycle kinetic studies in human cancers: Development of three DNA-specific labels in three decades. Arch Pathol Lab Med 115(9):873-879, 1991.
81. Raza A, Preisler H, Lampkin BC, Yousuf N, Tucker C, Peters N, White LM, Kukla C, Gartside P, Siegrist C, Bismayer J, Barcos M, Bennett J, Browman G, Goldberg J, Grunwald H, Larson R, Vardiman J, Vogler R: Biologic significance of cell cycle kinetics in 128 standard risk newly diagnosed patients with acute myelocytic leukemia. Br J Haematol 79(1):33-39, 1991.
80. Yousuf N, Yanik GA, George BA, Masterson M, Mazewski CM, White M, Miller MA, Lampkin BC, and Raza A: Comparison of two double labeling techniques to measure cell cycle kinetics in myeloid leukemias. Anticancer Res 11(3):1195-1200, 1991.
79. Miller MA, Mazewski CM, Yousuf N, Sheikh Y, White LM, Yanik GA, Hyams DM, Lampkin BC and Raza A: Simultaneous immunohistochemical detection of IUdR and BrdU infused intravenously to cancer patients. J Histochem Cytochem 39(4):407-412, 1991.
78. Raza A, Miller M, Mazewski C, Sheikh Y, Lampkin B, Sawaya R, Crone K, Berger T, Reising J, Gray J, Khan S and Preisler H: Observations regarding DNA replication sites in human cells in vivo following infusions of Iododeoxyuridine and Bromodeoxyuridine. Cell Prolif. 24(2):113-126, 1991.
77. Khan S, Raza A, Yousuf N, Barcos M, Saikia T, Masterson M, Bennett J, Browman G, Goldberg J, Grunwald H, Larson R, Sandberg A, Vogler R, Preisler HD: Cell cycle and clinical characteristics of patients with myeloproliferative disorders whose biopsies are reactive with anti-factor VIII antibody: A Leukemia Intergroup Study. Leuk Res 15 (1): 51-57, 1991.
76. Raza A, Mehdi I, Guo WJ Yousuf N, Masterson M, Mirto S, Motyka L, Mayers G: Detection of single-stranded DNA damage using monoclonal anti-thymidine antibody. Leuk Res 15(1):9-17, 1991.
75. Sato H, Preisler H, Day R, Raza A, Larson R, Browman G, Goldberg J, Vogler Grunwald H, Gottlieb A, Bennett J, Gottesman M and Pastan I: MDR1 transcript levels as an indication of resistant disease in acute myelogenous leukemia. Br J Haematol 75(3): 340-345, 1990.
74. Raza A, Preisler HD, Day R, Yasin Z, White LM, Lykins J, Barcos M, Bennett J, Browman G, Goldberg J, Grunwald H, Larson R and Vogler R: Direct relationship between remission duration in acute myeloid leukemia and cell cycle kinetics. A Leukemia Intergroup Study. Blood 76 (11):2191-2197, 1990.
73. Kolluri RV, Manuelidis L, Cremer T, Sait S, Gezer S and Raza A: Detection of monosomy 7 in interphase cells of patients with myeloid disorders. Am J Hematol 33(2):117-122 1990.
72. Raza A, Gezer S, Mehdi I, Preisler HD: Detection of BrdU in the regenerating bone marrow cells of a patient with AML. Leuk Res 13(12): 1055-1059, 1989.
71. Soni N, Mehdi I, Motyka, Mayers GL, Raza A: DNA damage/repair studies using a combination of monoclonal thymidine antibody and unscheduled DNA synthesis simultaneously. Anticancer Res 9(4):909-914, 1989.
70. Baer MR, Barcos M, Farrell H, Raza A, Preisler HD: Acute Myelogenous Leukemia with Leukemia Cutis: Eighteen Cases Seen Between 1969 and 1986. Cancer 63(11):2192-2200, 1989.
69. Preisler HD, Raza A, Larson R, LeBeau M, Browman G, Goldberg J, Grunwald H, Vogler R, Verkh L, Singh P, Block AM, Sandberg A: Proto-Oncogene Expression and the Clinical Characteristics of Acute Nonlymphocytic Leukemia: A Leukemia intergroup Pilot Study. Blood 73(1):255-262, 1989.
68. Browman G, Preisler H, Raza A, Syracuse K, Azarnia N, Benger A, Chervenick P, D’Arrigo P, Doeblin T, Goldberg J, Gottlieb A, Grunwald H, Kirshner J, Larson R, Meyer R, Miller K, Priore R, Stein M, Vogler WR, Walker I, Wilson WEC, Barcos M: Use of the Day 6 Bone Marrow to Alter Remission Induction Therapy in Patients with Acute Non-Lymphocytic Leukemia: A Leukemia Intergroup Study. Br J Haematol 71(4):493-497, 1989.
67. Raza A, Imren S, Gezer S, Verkh L and Freeman J: Expression of nucleolar antigen p145 in bone marrow cells of patients with myeloid leukemias. Cancer Res. 49(2):482-487, 1989.
66. Khan A, Raza A, Petrelli N, Mittleman A: In vivo determinations of labeling index in metastatic colorectal carcinoma and normal colonic mucosa using intravenous infusion of bromodeoxyuridine. J Surg Oncol 39(2)114-118, 1988.
65. Wang TY, Sreekantaiah C, Jani-Sait SN, Raza A and Sandberg AA: Letter to the Editor: Translocation (7;21) (p14;q11) in Ph-positive chronic myelogenous leukemia. Cancer Genet Cytogenet 33(2):225-227, 1988.
64. Wang TY, Raza A, Sait SN, Stein A, Schumer J and Sandberg A: A t (11;21) (q13;q22) in Ph-positive chronic myelogenous leukemia. Cancer Genet Cytogenet 31(2):187-191, 1988.
63. Gezer S, Yasin Z, Imren S and Raza A: Changes observed in the growth fraction labeling index, duration of S-phase and total cell cycle times of HL-60 cells as they undergo differentiation in response to retinoic acid. Cancer Res 48(21):5989-5994, 1988.
62. Raza A and Preisler HD: Correspondence: Differences in cell cycle characteristics among patients with acute nonlymphocytic leukemia. Blood 71 (2) 535-537, 1988.
61. Fan Y-S, Jani-Sait SN, Raza A, Rowe JM, D’Arrigo P, Sandberg AA: Translocation t (6;9) (p23;q34) in acute nonlymphocytic leukemia: Two new patients without increased bone marrow basophils. Letter to the Editor, Cancer Genet Cytogenet 32(1):153-155, 1988.
60. Raza A, Yasin Z and Grande C: A comparison of the rate of DNA synthesis in myeloblasts from peripheral blood and bone marrows of patients with acute nonlymphocytic leukemia. Exp Cell Res 176(1):13-19, 1988.
59. Wang T, Raza A, Fan Y, Jani-Sait SN, Kirshner J and Sandberg AA: Complex cytogenetic changes in Ph-negative chronic myelogenous leukemia. Cancer Genet Cytogenet 31(2):241-245, 1988.
58. Preisler HD and Raza A: Progress towards predictive models for the outcome of treatment for acute nonlymphocytic leukemia. Oncology 1(3):49-57, 1987.
57. Preisler HD and Raza A: Proto-oncogene transcript levels and acute nonlymphocytic leukemia. Semin Oncol 14(2):207-216, 1987.
56. Ohyashiki K, Ohyashiki JH, Otaki K, Yoshida MA, Raza A, Preisler HD and Sandberg AA: Four cases with complex Philadelphia translocation, including one with appearance de novo of a “masked” Ph. Cancer Genet Cytogenet 24(2):281-294, 1987.
55. Raza A, Maheshwari Y, Mandava N, Yasin Z, Perveen S, Mayers G, Browman G, Goldberg J, Gottlieb A, Grunwald H, Larson R, Miller K, Cell cycle and drug sensitivity studies of leukemic cells that appear relevant in determining response to chemotherapy in acute nonlymphocytic leukemia. Semin Oncol 14 (2) Suppl 1:217-225, 1987.
54. Raza A, Maheshwari Y, Yasin Z, Mandava N, Mayers GL and Preisler HD: A new method for studying cell cycle characteristics in ANLL using double-labeling with BrdU and 3HTdr. Leuk Res 11 (12):1079-1087, 1987.
53. Raza A, Maheshwari Y, Ucar K, Mayers G and Preisler HD: Proliferative characteristics of acute non-lymphocytic leukemia in vivo. Acta Hematological 77(3):140-145, 1987.
52. Preisler HD and Raza A: Chemotherapeutic strategies in the treatment of patients with acute nonlymphocytic leukemia in complete remission. Hematol Rev and Commun 2:13-43, 1987.
51. Ohyashiki K, Ohyashiki J, Kinniburgh A, Ryan D, Miller K, Raza A, Preisler HD and Sandberg AA: Transposition of breakpoint cluster region (3’bcr) in CML cells with variant Ph translocations. Cancer Genet Cytogenet 26(1):105-115, 1987.
50. Sait SNJ, Raza A, Sandberg AA: Tetrasomy of chromosome 8: An interesting and rare cytogenetic phenomenon in ANLL. Cancer Genet Cytogenet 27(2):269-271, 1987.
49. Sait SJ, Raza A and Sandberg AA: A t (1.11) in ANLL (M4). Cancer Genet Cytogenet 24(1):181-183, 1987.
48. Navone A and Raza A: Detection of DNA repair in BrdU versus Tdr containing DNA of individual cells by double-labeling technique. Anticancer Res 7(1):13-16, 1987.
47. Sailer M, Sait SJ and Raza A: Continued cell cycling ability of HL-60 cells following 3HaraC incorporation: A combination of “double-labeling” and sister chromatid analysis. Cancer genet Cytogenet 27(2):311-318, 1987.
46. Ohyashiki K, Ohyashiki JH, Raza A, Preisler HD and Sandberg AA: Phenylbutazone induced myelodysplastic syndrome with Philadelphia translocation. Cancer Genet Cytogenet 26(2):213-216, 1987.
45. Raza A, Maheshwari Y, Preisler HD: Differences in cell cycle characteristics amongst patients with acute nonlymphocytic leukemia. Blood 69(6):1647-1653, 1987.
44. Raza A, Maheshwari Y, Brereton W, Preisler HD: An analysis of cell cycle characteristics and course of disease in ANLL. Am J Hematol 24(1):65-75, 1987.
43. Ohyashiki JH, Ohyashiki K, Kinniburgh AJ, Raza A, Preisler HD and Sandberg AA: Bcr rearrangements in chronic myelogenous leukemia with a “masked” Ph-chromosome. Cancer Genet Cytogenet 25:15-20, 1987.
42. Preisler HD, Raza A, Early A, Kirshner J, Brecher M, Freeman A, Rustum Y, Azarnia N: Intensive remission consolidation therapy in the treatment of acute nonlymphocytic leukemia. J Clin Oncol 5(5):722-730, 1987.
41. Preisler HD, Raza A, Barcos M, Azarnia N, Larson R, Walker I, Browman M, Grunwald H, D’Arrigo P, Doeblin T, Bloom M, Stein A, Logue G, Goldberg J, Kirshner J, Gottlieb A, Bennett J: High-dose cytosine arabinoside as the initial treatment of poor-risk patients with acute nonlymphocytic leukemia: A Leukemia Intergroup Study. J Clin Oncol 5(1):75-82, 1987.
40. Preisler HD, Raza A, Barcos M, Azarnia N, Larson R, Browman M, Walker I, Grunwald H, D’Arrigo P, Stein A, Bloom M, Goldberg J, Gottlieb A, Bennett J, Kirshner J, Priore R: High dose cytosine arabinoside in the treatment of preleukemic disorders: A Leukemia Intergroup Study. Am J Hematol 23(2):131-134, 1986.
39. Preisler HD and Raza A: Predictors of response of acute nonlymphocytic leukemia. Cancer Invest 4(6):575-590, 1986.
38. Preisler HD, Raza A, Larson R, Browman G, Goldberg J, et al: Limited efficacy of four day course of high dose cytosine arabinoside in the treatment of poor risk patients with acute nonlymphocytic leukemia. Cancer Chemother Pharmacol 18(3):257-260, 1986.
37. Raza A and Preisler HD: Evidence of in vivo differentiation in myeloblasts labeled with bromodeoxyuridine. The Cancer J 1(1):15-18, 1986.
36. Raza A, Regal A-M, Takita H, Preisler HD: Fungal infection masquerading as acute pulmonary embolization. NYS J Med 86(4):207-209, 1986.
35. Preisler HD, Priore R, Azarnia N, Barcos M, Raza A, Rakowski I, Vogler R, Winton EL, Browman G, Goldberg J, Gottlieb AJ, Grunwald H, Rai K, Miller K, Brennan J, Chervenick P, Joyce R, Tricot G: Prediction of response of patients with acute nonlymphocytic leukemia to remission induction therapy: Use of clinical measurements. Br J Haematol 63(4):625-636, 1986.
34. Preisler HD, Raza A, Rustum Y and Browman G: The treatment of patients with acute nonlymphocytic leukemia in remission. Semin Oncol 12(2 Suppl 3):91-97, 1985.
33. Raza A and Preisler HD: Double labeling of human leukemic cells using 3H-cytarabine and monoclonal antibody against bromodeoxyuridine. Cancer Treat Rep 69 (2):195-198, 1985.
32. Raza A, Zhao SC, Kuliczkowski K and Preisler HD: Effects of cytosine arabinoside on DNA synthesis and mitotic activity of HL-60 cells. Med Oncol Tumor Pharmacother 2 (1):39-46, 1985.
31. Raza A, Kempski M, Block AMW and Preisler HD: A permanent method of detecting SCE by immunofluorescence using monoclonal anti-BrdU antibodies. Cancer Genet Cytogenet 15(1-2):187-189, 1985.
30. Raza A, Ucar K, Preisler HD and Mayers G: In vitro and in vivo assessment of sensitivity to araC in myeloid leukemias. Semin Oncol 12(2) suppl 3:9-19, 1985.
29. Raza A, Spiridonidis C, Zhao CS and Preisler HD: AraC incorporation into DNA. Blood 65(1):245-246, 1985.
28. Abe R. Raza A, Preisler HD, Tebbi CK, Sandberg A: Chromosomes and causation of human cancer and leukemia LIV. Near-tetraploidy in acute leukemia. Cancer Genet Cytogenet 14(1-2):45-59, 1985.
27. Raza A, Bhayana R, Ucar K, Kirshner J and Preisler HD: Differences between labeling index and DNA histograms in assessing S-phase cells from a homogenous group of chronic phase CML patients. Cytometry 6(5):445-451, 1985.
26. Raza A, Ucar K, Bhayana R, Kempski M and Preisler HD: Utility and sensitivity of anti-BrdU antibodies in assessing S-phase cell compared to autoradiography. Cell Biochem Funct 3(2):149-153, 1985.
25. Raza A and Preisler HD: Peer Review. Ann Intern Med 103 (3):470-471, 1985.
24. Kirshner J, Preisler HD and Raza A: Lack of relationship between in vitro cell measurement and response to busulfan in chronic myelocytic leukemia. Am J Hematol 18:191-200, 1985.
23. Raza A, Ucar K and Preisler HD: Double labeling and in vitro versus in vivo incorporation of bromodeoxyuridine in patients with acute nonlymphocytic leukemia. Cytometry 6(6):633-640, 1985.
22. Preisler HD, Raza A and Barcos M: Treatment of dysmyelopoietic leukemic syndrome with myelofibrosis and megakaryocytic hyperplasia with large doses of cytosine arabinoside. Med Oncol Tum Pharmacother 2 (2):87-91, 1985.
21. Spiridonidis C, Raza A, Zhao SC and Preisler HD: Improved rapid autoradiography with elimination of background. Cell Biochem Funct 3(2):147-148, 1985.
20. Raza A, Spiridonidis C, Ucar K, Bankert R, Mayers G and Preisler HD; Double labeling of S-phase murine cells with bromodeoxyuridine and a second DNA specific probe. Cancer Res 45:2283-2287, 1985.
19. Raza A, Raza AS, Kuliczkowski K, Zhao SC and Preisler HD: Comparison of autoradiography and DNA histograms in assessing S-phase cells from patients with myeloid leukemias. Med Oncol Tumor Pharmacother 2 (4) :269-279, 1985.
18. Raza A, Gill LM, Rakowski I and Preisler HD: Spontaneous remission in acute myelocytic leukemia. NYS J Med 85 (6):269-270, 1985.
17. Preisler HD, Raza A, Azarnia A, Rakowski I, Barcos M, Browman G, Goldberg J, Gottleib A, et al: Changes in the characteristics of the bone marrow during therapy for acute non-lymphocytic leukemia: Relationship to response to remission induction therapy. Eur J Cancer Clin Oncol 21 (5):563-571, 1985.
16. Preisler HD and Raza A: In vitro assessment of drug sensitivity in acute nonlymphocytic leukemia. Recent Results Cancer Research 94:102-115, 1984.
15. Preisler HD, Raza A, Higby DJ, Krishner J, Woll J, Bennett J, Winton L, Weiner R, Richman C, Golomb H and Goldberg J: Treatment of myeloid blastic crisis of chronic myelogenous leukemia. Cancer Treat Rep 68 (11):1351-1355, 1984.
14. Raza A and Preisler HD: Use of BrdU and 3HTdr for double labeling of human leukemic cells. Biotechniques 2 (4):262-266, 1984.
13. Costanzo C and Raza A: Immunofluorescent staining method for use with monoclonal antibodies. Cell Biochem & Funct 2(3):153-154, 1984.
12. Raza A, Preisler HD, Mayers GL and Bankert R: Rapid enumeration of S-phase cells by means of monoclonal antibodies. N Engl J Med 310 (15):991, 1984.
11. Preisler HD, Epstein J, Raza A, Azarnia N, Browmman G, Booker L, Goldberg J, Gottleib A, Brennan J, Grunwald H: Inhibition of DNA synthesis by cytosine arabinoside: Relation to response of acute nonlymphocytic leukemia to remission induction therapy and to stage of the disease. Eur J Cancer Clin Oncol 20 (8):1061-1068, 1984.
10. Raza A, Minowada J, Barcos M, Rakowski I and Preisler HD: Philadelphia positive acute leukemia. Eur J of Cancer Clin Oncol 20(12):1509-1516, 1984.
9. Preisler HD, Azarnia N, Raza A, Grunwald H, Vogler WR, Browman G, Goldberg J, Chervenick P, Miller KB and Brennan J: Relationship between the percent of marrow cells in S-phase and the outcome of remission induction therapy for acute non-lymphocytic leukemia. Br J Haematol 56 (3) :399-407, 1984.
8. Preisler HD, Epstein J, Barcos M, Priore R, Raza A, Browman GP, Vogler R, Winton E, Grunwald H, Rai K, Brennan J, Bennett J, Goldberg J, Gottlieb A, Cherrenick P, Joyce R, Miller K, Larson R, D’Arrigo P, Doeblin T, Stein M, Bloom M, Steele R and Lee H: Prediction of response of acute nonlymphocytic leukemia to therapy with “high dose” cytosine arabinoside. Br J Haematol 58 (1) :19-32, 1984.
7. Raza A, Kuliczkowski K, Weidong G and Preisler HD: Comparison of in vitro assays for detecting subpopulations resistant to araC. Med Oncol Tumor Pharmacother 1(3) :163-168, 1984.
6. Preisler HD, Raza A: Uptake of Adriamycin by human leukemic cells as measured by flow cytometry. Med Oncol Tumor Pharmacother 1(1):43-48, 1984.
5. Preisler HD, Early AP, Raza A, Vlahides G, Marinello MJ, Stein AM and Browman G: Therapy of secondary acute non-lymphocytic leukemia – Reply. N Engl J Med 308 (1) :1295-1296, 1983.
4. Preisler HD, Early A, Raza A Vhahides G, Marinello M, Browman G and Stein A: Therapy of secondary acute non-lymphocytic leukemia with cytarabine. N Engl J Med 308 (1) :21-23, 1983.
3. Preisler HD and Raza A: Chronic myelocytic leukemia: Comments on New Approaches to Therapy. Cancer Treat Rep 66(5): 1073-1076, 1982.
2. Preisler HD, Brecher M, Browman G, Early AP, Walker IR, Raza A, and Freeman, A: Treatment of AML in patients 30 years of age and younger. Am J Hematol 13(3):189-198, 1982.
1. Raza A: Comparison of labeling indices in peripheral blood and bone marrow of patients in chronic phase of CML – A review of literature. Annual Research Report at RPMI, 1981.
15. Raza A, Qawi H, Medhi M, Mumtaz M, Galili N. Translational Research in MyelodysplasticSyndromes. In volume of series, “ Reviews in Clinical and Experimental Hematology ,” R Foa and V A Hoffbrand (editors): PP 1-13, 2004